Incidence, characteristics and management of recently diagnosed, microscopically invasive breast cancer by receptor status: Iowa SEER 2000-2013

Abstract Background Recent incidence, treatment patterns and outcomes for node negative microscopically invasive breast cancer (MIBC) have not been reported. Methods State Health Registry of Iowa data identified women with ductal carcinoma in situ (DCIS), MIBC, and Stage I breast cancer excluding MI...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of surgery 2017-08, Vol.214 (2), p.323-328
Main Authors: Thomas, Alexandra, MD, Weigel, Ronald J., MD, PhD, Lynch, Charles F., MD, PhD, Spanheimer, Philip M., MD, Breitbach, Elizabeth K., MD, Schroeder, Mary C., PhD
Format: Article
Language:English
Subjects:
Biopsy
Breast cancer
Breast neoplasms
Breast Neoplasms - chemistry
Breast Neoplasms - epidemiology
Breast Neoplasms - pathology
Breast Neoplasms - therapy
Cancer
Cancer incidence
Carcinoma, Intraductal, Noninfiltrating - chemistry
Carcinoma, Intraductal, Noninfiltrating - epidemiology
Carcinoma, Intraductal, Noninfiltrating - pathology
Carcinoma, Intraductal, Noninfiltrating - therapy
Chemotherapy
Epidermal growth factor
Female
Humans
Incidence
Invasiveness
Iowa
Mammography
Mastectomy
Methyl isobutyl carbinol
Microinvasive tumor
Middle Aged
Neoplasm Invasiveness
Neoplasm Staging
Receptor, ErbB-2 - analysis
SEER Program
Surgery
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Recent incidence, treatment patterns and outcomes for node negative microscopically invasive breast cancer (MIBC) have not been reported. Methods State Health Registry of Iowa data identified women with ductal carcinoma in situ (DCIS), MIBC, and Stage I breast cancer excluding MIBC (Stage 1BC). Results From 2000-2013, 1,706, 193 and 4,514 women were diagnosed with DCIS, MIBC and Stage 1BC, respectively. MIBC increased at an annual percentage change of 2.1 (p=0.041). MIBC was more frequently human epidermal-growth-factor-receptor-2 positive than Stage 1BC (39.7% vs 9.6%, p
ISSN:0002-9610
1879-1883
DOI:10.1016/j.amjsurg.2016.08.008